Deep Apple Therapeutics
Accelerating drug discovery with structure-based large library virtual screening and deep learning models
Accelerating drug discovery with structure-based large library virtual screening and deep learning models
Deep Apple Therapeutics is a biotechnology startup that specializes in accelerating drug discovery through structure-based large library virtual screening and deep learning models. The company's focus on exploring the unexplored virtual chemical space sets it apart, using ensemble cryo-EM, deep learning, and the docking of multi-billion compound libraries generated using their proprietary Orchard.ai™ algorithm. Founded in 2022 and headquartered in the United States, Deep Apple Therapeutics secured a significant $52.00M Series A investment on 14 December 2023, with support from Apple Tree Partners.
Deep Apple's edge lies in its founders' expertise in computational modeling, protein and target structure determination, large-scale molecular docking, and the elucidation of protein dynamics and conformational transitions. This structure-based, machine learning-driven drug design approach empowers the company to rapidly advance novel candidates targeting well-validated inflammatory, metabolic, and endocrine disease targets. For further details, visit deepappletx.com.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $52.00M | 1 |
|
14 Dec 2023 |
No recent news or press coverage available for Deep Apple Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
